Cargando…
Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has been identified as the causal agent of COronaVIrus Disease‐19 (COVID‐19), an atypical pneumonia‐like syndrome that emerged in December 2019. While SARS‐CoV‐2 titers can be measured by detection of viral nucleic acid, this method is una...
Autores principales: | Mendoza, Emelissa J., Manguiat, Kathy, Wood, Heidi, Drebot, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300432/ https://www.ncbi.nlm.nih.gov/pubmed/32475066 http://dx.doi.org/10.1002/cpmc.105 |
Ejemplares similares
-
Loss of repeat convalescent plasma donors due to waning anti-SARS-CoV-2 plaque reduction neutralization test titers (April-December 2020)
por: Drews, Steven, et al.
Publicado: (2022) -
Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
por: Valcourt, Emelissa J., et al.
Publicado: (2021) -
Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test
por: Merluza, John, et al.
Publicado: (2023) -
Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays
por: Valcourt, Emelissa J., et al.
Publicado: (2021) -
Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
por: Sekirov, Inna, et al.
Publicado: (2021)